A battle for profits between two arms of the health-care industry has made privately insured patients into pawns, offering them a growing number of discounts on their drug co-pays while ultimately leaving them with fewer drug options overall, according to a new analysis.

The research, funded by Pfizer, found that the number of coupons that drug companies o...